Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients

Journal of Medical Virology

Volumn 74, Issue 1, 2004, Pages 16-20

  Marcelin, Anne Geneviève ^a,c   Affolabi, Dissou ^a   Lamotte, Claire ^b   Mohand, Hocine Ait ^a   Delaugerre, Constance ^a   Wirden, Marc ^a   Voujon, Delphine ^a   Bossi, Philippe ^a   Ktorza, Nadine ^a   Bricaire, François ^a   Costagliola, Dominique ^a   Katlama, Christine ^a   Peytavin, Gilles ^b   Calvez, Vincent ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b BICHAT HOSPITAL   (France)

^c Department of Virology ^*  (France)

Author keywords

Amprenavir; Failure; Mutations; Plasma concentration; Selection

Indexed keywords

AMPRENAVIR; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; TREATMENT FAILURE; VIRUS LOAD; VIRUS MUTATION;

ADULT; AMINO ACID SUBSTITUTION; CARBAMATES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; RITONAVIR; SELECTION (GENETICS); SULFONAMIDES; TREATMENT FAILURE; VIRAL LOAD; VIREMIA;

EID: 3342951974     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20140     Document Type: Article

References (24)

1. Ait-Khaled M, Rakik A, Griffin P, Stone C, Richards N, Thomas D, Falloon J, Tisdale M. 2003. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study. Antivir Ther 8:111-120.
2. Boden D, Markowitz M. 1998. Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother 42:2775-2783.
3. Condra JH. 1998. Resistance to HIV protease inhibitors. Haemophilia 4:610-615.
4. De Jesus E, La Marca A, Sension M, Beltran C, Yeni P. 10-14 February, 2003. The Context study: Efficacy and safety of GW433908/RTV in PI-experienced subjects with virological failure (24 weeks results), 10th Conference on Retroviruses and Opportunistic Infections, Boston, USA.
5. Delfraissy JF. 2000. Prise en charge thérapeutique des personnes infectées par le VIH. Médecine-Sciences.
6. Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L, Lamarre D. 1996. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol 70:3763-3769.
7. Elston R, Randall S, Xu F, Harris W, Manohitharajah V, Maguire M, Rakik A, Ait-Khaled M, Stein DS, Tisdale M, Snowden W. 2-4 April, 2001. High plasma trough levels favour the selection of the I50V mutation pathway during development of APV resistance, 2nd International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, The Netherlands.
8. Jung M, Agut H, Candotti D, Ingrand D, Katlama C, Huraux J. 1992. Suceptibility of HIV-1 isolates to zidovudine: Correlation between widely applicable culture test and PCR analysis. J Acquir Immune Defic Syndr 5:359-364.
9. Larder BA, Kellam P, Kemp SD. 1991. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 5:137-144.
10. Maguire M, Shortino D, Klein A, Harris W, Manohitharajah V, Tisdale M, Elston R, Yeo J, Randall S, Xu F, Parker H, May J, Snowden W. 2002. Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: Selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob Agents Chemother 46:731-738.
11. Marcelin AG, Lamotte C, Delaugerre C, Ktorza N, Ait Mohand H, Cacace R, Bonmarchand M, Wirden M, Simon A, Bossi P, Bricaire F, Costagliola D, Katlama C, Peytavin G, Calvez V. 2003. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother 47:594-600.
12. Markowitz M, Mo H, Kempf DJ, Norbeck DW, Bhat TN, Erickson JW, Ho DD. 1995. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol 69:701-706.
13. Marsh KC, Eiden E, McDonald E. 1997. Determination of ritonavir, a new HIV protease inhibitor, in biological samples using reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 704:307-313.
14. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, Markowitz M, Chernyavskiy T, Niu P, Lyons N, Hsu A, Granneman GR, Ho DD, Boucher CA, Leonard JM, Norbeck DW, Kempf DJ. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 2:760-766.
15. Nadler JP, Gathe JC, Pollard RB, Richmond GJ, Liao Q, Griffith S, Tracey Lancaster C, Hernandez JE, Pappa KA. 2003. Twice-daily amprenavir 1,200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients. BMC Infect Dis 3:10.
16. Nijhuis M, Boucher CA, Schipper P, Leitner T, Schuurman R, Albert J. 1998. Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. Proc Natl Acad Sci USA 95:14441-14446.
17. Noble S, Goa KL. 2000. Amprenavir: A review of its clinical potential in patients with HIV infection. Drugs 60:1383-1410.
18. Partaledis JA, Yamaguchi K, Tisdale M, Blair EE, Falcione C, Maschera B, Myers RE, Pazhanisamy S, Futer O, Cullinan AB, et al. 1995. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol 69:5228-5235.
19. Pazhanisamy S, Partaledis JA, Rao BG, Livingston DJ. 1998. In vitro selection and characterization of VX-478 resistant HIV-1 variants. Adv Exp Med Biol 436:75-83.
20. Sadler BM, Hanson CD, Chittick GE, Symonds WT, Roskell NS. 1999. Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults. Antimicrob Agents Chemother 43:1686-1692.
21. Sadler BM, Piliero PJ, Preston SL, Lloyd PP, Lou Y, Stein DS. 2001. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers. Aids 15:1009-1018.
22. Schmidt B, Korn K, Moschik B, Paatz C, Uberla K, Walter H. 2000. Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors. Antimicrob Agents Chemother 44:3213-3216.
23. Tisdale M, Myers RE, Maschera B, Parry NR, Oliver NM, Blair ED. 1995. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother 39:1704-1710.
24. Tisdale M, Myers R, Randall S, Maguire M, Ait-Khaled M, Elston R, Snowden W. 2000. Evolution of resistance to the protease inhibitor amprenavir in vitro and in clinical studies. Clin Drug Investig 20:267-285.